[HTML][HTML] Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO)
The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
(DOACs) offers some major advantages over warfarin and other vitamin K antagonists …
Pharmacokinetics of direct oral anticoagulants in patients with atrial fibrillation and extreme obesity
V Russo, D Cattaneo, L Giannetti, R Bottino… - Clinical Therapeutics, 2021 - Elsevier
Abstract Purpose Direct oral anticoagulants (DOACs) are recommended in preference to
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - International journal of …, 2020 - Elsevier
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Effectiveness and safety of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and weighing≥ 120 kilograms versus 60–120 kilograms
EE Wiethorn, CM Bell, BS Wiggins - American Journal of Cardiovascular …, 2021 - Springer
Abstract Background Direct oral anticoagulants (DOACs) have become favorable choices for
anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non …
anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non …
Direct oral anticoagulants in obesity: an updated literature review
J Sebaaly, D Kelley - Annals of Pharmacotherapy, 2020 - journals.sagepub.com
Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation
K Kido, S Ngorsuraches - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or …
AR Novak, C Shakowski, TC Trujillo, GC Wright… - Journal of Thrombosis …, 2022 - Springer
Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …
extremes of body weight remains controversial. This study aimed to measure the impact of …
Italian intersociety consensus on DOAC use in internal medicine
D Prisco, W Ageno, C Becattini, A D'Angelo… - Internal and emergency …, 2017 - Springer
The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the
prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the …
prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the …
[HTML][HTML] Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Ł Wołowiec, M Kusiak, J Budzyński… - Journal of Clinical …, 2023 - mdpi.com
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …
[HTML][HTML] Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K Martin, J Beyer‐Westendorf, BL Davidson… - Journal of Thrombosis …, 2016 - Elsevier
Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …
相关搜索
- hospital cardiologists patients with obesity
- hospital cardiologists atrial fibrillation
- atrial fibrillation patients with obesity
- oral anticoagulants fibrillation experience
- atrial fibrillation body weights
- atrial fibrillation efficacy outcomes
- atrial fibrillation evaluation of safety
- atrial fibrillation venous thromboembolism
- atrial fibrillation extreme obesity
- atrial fibrillation efficacy and safety